Candel Therapeutics (NASDAQ:CADL) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Candel Therapeutics (NASDAQ:CADL) in a report published on Wednesday morning,Benzinga reports. They currently have a $19.00 target price on the stock. HC Wainwright also issued estimates for Candel Therapeutics’ FY2025 earnings at ($1.39) EPS.

A number of other research firms have also weighed in on CADL. Bank of America began coverage on Candel Therapeutics in a research note on Friday, February 7th. They set a “buy” rating and a $15.00 price objective on the stock. Citigroup began coverage on Candel Therapeutics in a research note on Thursday, February 20th. They set a “buy” rating and a $25.00 price objective on the stock. Finally, Canaccord Genuity Group began coverage on Candel Therapeutics in a research note on Wednesday, February 19th. They set a “buy” rating and a $20.00 price objective on the stock.

Candel Therapeutics Stock Performance

NASDAQ CADL opened at $8.98 on Wednesday. The stock’s fifty day moving average is $8.35 and its two-hundred day moving average is $6.75. The firm has a market capitalization of $291.63 million, a P/E ratio of -5.19 and a beta of -1.25. Candel Therapeutics has a fifty-two week low of $1.34 and a fifty-two week high of $14.60.

Insider Buying and Selling at Candel Therapeutics

In other Candel Therapeutics news, insider Francesca Barone sold 13,673 shares of Candel Therapeutics stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $8.22, for a total value of $112,392.06. Following the sale, the insider now owns 124,207 shares in the company, valued at $1,020,981.54. The trade was a 9.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CTO Seshu Tyagarajan sold 14,322 shares of Candel Therapeutics stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $7.22, for a total value of $103,404.84. Following the completion of the sale, the chief technology officer now owns 96,790 shares in the company, valued at $698,823.80. This represents a 12.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 41,529 shares of company stock worth $313,512 over the last quarter. 41.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Candel Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC raised its holdings in shares of Candel Therapeutics by 86.6% in the 4th quarter. Squarepoint Ops LLC now owns 19,311 shares of the company’s stock valued at $168,000 after buying an additional 8,962 shares during the period. Nuveen Asset Management LLC raised its holdings in shares of Candel Therapeutics by 3.0% in the 4th quarter. Nuveen Asset Management LLC now owns 68,226 shares of the company’s stock valued at $592,000 after buying an additional 2,009 shares during the period. Maven Securities LTD purchased a new stake in shares of Candel Therapeutics in the 4th quarter valued at $449,000. Millennium Management LLC raised its holdings in shares of Candel Therapeutics by 130.6% in the 4th quarter. Millennium Management LLC now owns 31,626 shares of the company’s stock valued at $275,000 after buying an additional 17,914 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Candel Therapeutics by 12.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,165 shares of the company’s stock valued at $106,000 after buying an additional 1,340 shares during the period. Hedge funds and other institutional investors own 13.93% of the company’s stock.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.